Intravenous nicorandil for patients with acute decompensated heart failure: a meta-analysis of randomized controlled trials

References

• Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023; 118(17):3272–3287.
   PubMed Web of Science ®Google Scholar
• Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2022 update: a report from the American heart association. Circulation. 2022; 145(8):e153–e639.
   PubMed Web of Science ®Google Scholar
• Arrigo M, Jessup M, Mullens W, et al. Acute heart failure. Nat Rev Dis Primers. 2020; 6(1):16.
   PubMed Web of Science ®Google Scholar
• Behnoush AH, Khalaji A, Naderi N, et al. ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison. ESC Heart Fail. 2023; 10(3):1531–1544.
   PubMedGoogle Scholar
• Frampton J, Buckley MM, Fitton A. Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris. Drugs. 1992; 44(4):625–655.
   PubMed Web of Science ®Google Scholar
• Gvishiani M, Gabunia L, Makharadze T, et al. Nicorandil efficacy in the treatment of ischemic heart disease (review). Georgian Med News. 2018; (280-281):152–155.
   PubMedGoogle Scholar
• Ahmed LA. Nicorandil: a drug with ongoing benefits and different mechanisms in various diseased conditions. Indian J Pharmacol. 2019; 51(5):296–301.
   PubMed Web of Science ®Google Scholar
• Horinaka S. Use of nicorandil in cardiovascular disease and its optimization. Drugs. 2011; 71(9):1105–1119.
   PubMed Web of Science ®Google Scholar
• Zhao F, Chaugai S, Chen P, et al. Effect of nicorandil in patients with heart failure: a systematic review and meta-analysis. Cardiovasc Ther. 2014; 32(6):283–296.
   PubMed Web of Science ®Google Scholar
• Singh A, Laribi S, Teerlink JR, et al. Agents with vasodilator properties in acute heart failure. Eur Heart J. 2017; 38(5):317–325.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71.
   PubMed Web of Science ®Google Scholar
• Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021; 372:n160.
   PubMed Web of Science ®Google Scholar
• Higgins J, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.2. London, UK: The Cochrane Collaboration. 2021. www.training.cochrane.org/handbook.
   Google Scholar
• McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure: the framingham study. N Engl J Med. 1971; 285(26):1441–1446.
   PubMed Web of Science ®Google Scholar
• Weber CK, Miglioranza MH, Moraes MA, et al. The five-point Likert scale for dyspnea can properly assess the degree of pulmonary congestion and predict adverse events in heart failure outpatients. Clinics. 2014;69(5):341–346.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539–1558.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003; Sep 6327(7414):557–560.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629–634.
   PubMed Web of Science ®Google Scholar
• Shirakabe A, Hata N, Yokoyama S, et al. Efficacy and safety of nicorandil therapy in patients with acute heart failure. J Cardiol. 2010; 56(3):339–347.
   PubMed Web of Science ®Google Scholar
• Kasama S, Toyama T, Funada R, et al. Effects of adding intravenous nicorandil to standard therapy on cardiac sympathetic nerve activity and myocyte dysfunction in patients with acute decompensated heart failure. Eur J Nucl Med Mol Imaging. 2015; 42(5):761–770.
   PubMed Web of Science ®Google Scholar
• Harada K, Yamamoto T, Okumura T, et al. Intravenous nicorandil for treatment of the urgent phase acute heart failure syndromes: a randomized, controlled trial. Eur Heart J Acute Cardiovasc Care. 2017; 6(4):329–338.
   PubMed Web of Science ®Google Scholar
• Li YD, Zhang ML, Wang X, et al. Efficacy and safety of intravenous nicorandil combined with conventional therapy in patients with acute heart failure. Sandong Med J. 2018;58(17):49–51.
   Google Scholar
• Xie YS, Zou L. Therapeutic effect of nicorandil combined with conventional therapy in patients with acute heart failure. J Qiqihar Med Univ. 2018;39(19):2290–2292.
   Google Scholar
• Gan YH. The study of nicorandil combined with recombinant human brain natriuretic peptide in the treatment of acute heart failure. Pract Clin J Integr Trad Chin West Med. 2021;2021(21):6.
   Google Scholar
• Yang CZ, Li J, Ren ZL, et al. Clinical effect of nicorandil combined with dopamine in the treatment of elderly patients with acute heart failure. Clin J Med Offic. 2022;50(7):745–750.
   Google Scholar
• Zhang Y, Cai Z, Ke X, et al. Effectiveness and safety of intravenous nicorandil application in patients with acute heart failure with low baseline blood pressure. Heart Lung Circ. 2022; 31(1):95–100.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhao C, Zhang H, et al. Dyspnea measurement in acute heart failure: a systematic review and evidence map of randomized controlled trials. Front Med . 2021;8:728772.
   Google Scholar
• Hendricks S, Dykun I, Balcer B, et al. Higher BNP/NT-pro BNP levels stratify prognosis equally well in patients with and without heart failure: a meta-analysis. ESC Heart Fail. 2022; 9(5):3198–3209.
   PubMed Web of Science ®Google Scholar
• Nagueh SF, Middleton KJ, Kopelen HA, et al. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol. 1997; 30(6):1527–1533.
   PubMed Web of Science ®Google Scholar
• Matsushita K, Minamishima T, Sakata K, et al. Differences in predictors of one-year mortality between patients with hypertensive and non-hypertensive acute heart failure: usefulness of E/E' in hypertensive heart failure. Eur J Intern Med. 2017; 38:e13–e14.
   PubMed Web of Science ®Google Scholar
• Zamfirescu MB, Ghilencea LN, Popescu MR, et al. The E/e’ ratio-role in risk stratification of acute heart failure with preserved ejection fraction. Medicina. 2021; 57(4):375.
   PubMedGoogle Scholar
• Ishihara S, Koga T, Kaseda S, et al. Effects of intravenous nicorandil on the mid-term prognosis of patients with acute heart failure syndrome. Circ J. 2012;76(5):1169–1176.
   PubMed Web of Science ®Google Scholar
• Larsen AI, Goransson L, Aarsland T, et al. Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure. Am Heart J. 1997; 134(3):435–441.
   PubMed Web of Science ®Google Scholar
• Bravo PE, Di Carli MF, Dorbala S. Role of PET to evaluate coronary microvascular dysfunction in non-ischemic cardiomyopathies. Heart Fail Rev. 2017; 22(4):455–464.
   PubMed Web of Science ®Google Scholar
• Tona F, Montisci R, Iop L, et al. Role of coronary microvascular dysfunction in heart failure with preserved ejection fraction. Rev Cardiovasc Med. 2021; 22(1):97–104.
   PubMed Web of Science ®Google Scholar
• Hirose M, Takeishi Y, Nakada T, et al. Nicorandil prevents galphaq-induced progressive heart failure and ventricular arrhythmias in transgenic mice. PLoS One. 2012;7(12):e52667.
   PubMed Web of Science ®Google Scholar